KRMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KRMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. KORU Medical Systems's Average Total Inventories for the quarter that ended in Sep. 2024 was $3.26 Mil. KORU Medical Systems's Revenue for the three months ended in Sep. 2024 was $8.18 Mil. KORU Medical Systems's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.40.
KORU Medical Systems's Inventory-to-Revenue for the quarter that ended in Sep. 2024 increased from Jun. 2024 (0.34) to Jun. 2024 (0.40)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueDays Inventory indicates the number of days of goods in sales that a company has in the inventory. KORU Medical Systems's Days Inventory for the three months ended in Sep. 2024 was 99.31.
Inventory Turnover measures how fast the company turns over its inventory within a year. KORU Medical Systems's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.92.
The historical data trend for KORU Medical Systems's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KORU Medical Systems Annual Data | |||||||||||||||||||||
Trend | Feb14 | Feb15 | Feb16 | Feb17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Inventory-to-Revenue | Get a 7-Day Free Trial | 0.10 | 0.19 | 0.28 | 0.22 | 0.17 |
KORU Medical Systems Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Inventory-to-Revenue | Get a 7-Day Free Trial | 0.71 | 0.57 | 0.40 | 0.34 | 0.40 |
For the Medical Instruments & Supplies subindustry, KORU Medical Systems's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where KORU Medical Systems's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
KORU Medical Systems's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
Inventory-to-Revenue (A: Dec. 2023 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) |
= | ( (6.405 | + | 3.481) | / | 2 ) | / | 28.518 |
= | 4.943 | / | 28.518 | ||||
= | 0.17 |
KORU Medical Systems's Inventory-to-Revenue for the quarter that ended in Sep. 2024 is calculated as
Inventory-to-Revenue (Q: Sep. 2024 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (Q: Jun. 2024 ) | + | Total Inventories (Q: Sep. 2024 )) | / | count ) | / | Revenue (Q: Sep. 2024 ) |
= | ( (2.589 | + | 3.928) | / | 2 ) | / | 8.18 |
= | 3.2585 | / | 8.18 | ||||
= | 0.40 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KORU Medical Systems (NAS:KRMD) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueLikewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenueMore Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
KORU Medical Systems's Days Inventory for the three months ended in Sep. 2024 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Sep. 2024 ) | / | Cost of Goods Sold (Q: Sep. 2024 ) | * | Days in Period |
= | 3.2585 | / | 2.994 | * | 365 / 4 | |
= | 99.31 |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
KORU Medical Systems's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Sep. 2024 ) | / | Average Total Inventories (Q: Sep. 2024 ) |
= | 2.994 | / | 3.2585 | |
= | 0.92 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of KORU Medical Systems's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Manko Joseph M. Jr. | 10 percent owner | 1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103 |
Kenneth E Miller | officer: Chief Commercial Officer | 26 MOUNTAINVIEW RD, WARREN NJ 07059 |
Edward Wholihan | director | C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462 |
Linda M Tharby | officer: President and CEO | BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417 |
Robert Cascella | director | C/O HOLOGIC, INC., BEDFORD MA 01730 |
Lafrence Andrew D.c. | officer: Chief Financial Officer | C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070 |
Thomas Edward Adams | officer: Interim CFO | 524 WOODLAND AVENUE, BRIELLE NJ 08730 |
Brian Case | officer: Chief Technology Officer | 424 CYPRUS CIR, LAKE VILLA IL 60046-8629 |
Shahriar Matin | director | 96 TALAMINE COURT, COLORADO SPRINGS CO 80907 |
Donna French | director | 25 SEARSVILLE COURT, HILLSBOROUGH CA 94010 |
Donald B Pettigrew | officer: Pres./Chief Commercial Officer | 7871 ENGEN LOOP, PARK CITY UT 84098 |
Karen Fisher | officer: CFO | 24 CARPENTER ROAD, CHESTER NY 10918 |
Daniel S Goldberger | director | 24 CARPENTER ROAD, CHESTER NY 10918 |
R John Fletcher | director | C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070 |
Horton Freedom, L.p. | 10 percent owner | 1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103 |
From GuruFocus
By GuruFocus Research • 05-01-2024
By Business Wire • 07-25-2024
By GuruFocus News • 11-14-2024
By Business Wire • 03-18-2024
By GuruFocus Research • 08-08-2024
By Business Wire • 03-11-2024
By Business Wire • 07-24-2024
By Business Wire • 05-14-2024
By Business Wire • 02-21-2024
By Business Wire • 06-04-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.